<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31718">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01827618</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20120135H</org_study_id>
    <secondary_id>KL2 TR000118-05/CTSA</secondary_id>
    <nct_id>NCT01827618</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy</brief_title>
  <official_title>An Immunopharmacodynamic Phase 0/I Study of Rapamycin in Patients Undergoing Radical Cystectomy for Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the effects of rapamycin directly on bladder tumors and the
      effects of rapamycin on the immune system of patients with bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a presurgical clinical trial which aims to understand the biologic activity of TORC1
      inhibition and safety in patients with bladder cancer.  In this presurgical setting, paired
      PMBCs and tumor tissue is evaluated before and after exposure to rapamycin to address target
      specificity, drug delivery, physiologic effects on tumor growth and apoptosis, and
      correlation of biomarkers with clinical activity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Tissue pharmacodynamic (PD) response to TORC1 inhibition</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>PD response defined by significant phospho rpS6 Kinase 1 (S6K1) inhibition (comparing post-treatment to baseline).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Invasive Bladder Cancer Stage II</condition>
  <arm_group>
    <arm_group_label>Rapamycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapamycin 3mg orally daily x 4weeks prior to radical cystectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin</intervention_name>
    <arm_group_label>Rapamycin</arm_group_label>
    <other_name>Sirolimus, Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have invasive (â‰¥T1) bladder cancer

          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          3. In their treating physician's opinion is a good candidate for radical cystectomy

          4. In their treating physician's opinion does not need neoadjuvant chemotherapy prior to
             cystectomy

          5. Be able to give informed consent

          6. Be age 18 or older

          7. Have adequate marrow function (defined as granulocytes greater than 1,500 cells/mm3
             hemoglobin &gt;9.5 gm/dl or platelets more than 100,000 cells/mm3).

          8. Have adequate end-organ function (GFR &gt;30, bilirubin &lt;1.5, SGOT &lt; 3x ULN)

          9. Have a life expectancy &gt; one year

         10. Not have a prior history of non-bladder cancer unless the cancer is clinically stable
             and not requiring active treatment

         11. Not have received chemotherapy or radiotherapy in the prior 30 days

        Exclusion Criteria:

          1. Immunosuppressed state (e.g. HIV, use of chronic steroids)

          2. Fixed disease (clinical T4)

          3. Active, uncontrolled infections

          4. Hepatic impairment (SGOT &gt;3x ULN)

          5. Unhealed wounds

          6. Patients at risk of pregnancy who are unwilling or unable to take effective
             contraception before rapamycin therapy, during therapy, and for 12 weeks after
             discontinuation of therapy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert S Svatek, MD,MSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Health Science Center San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Izelda Zarate</last_name>
    <phone>210-567-5676</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Svatek, MD, MSCI</last_name>
    <phone>210-567-5676</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UT Health Science Center San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Izelda Zarate</last_name>
      <phone>210-567-5676</phone>
      <email>zarateI@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eva Garcia</last_name>
      <phone>210-567-1590</phone>
      <email>garciaee@uthscsa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tyler J Curiel, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 10, 2013</lastchanged_date>
  <firstreceived_date>March 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Robert Svatek</investigator_full_name>
    <investigator_title>Assistant Professor, Division of Urologic Oncology</investigator_title>
  </responsible_party>
  <keyword>bladder</keyword>
  <keyword>Cancer</keyword>
  <keyword>Cystectomy</keyword>
  <keyword>Rapamycin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
